Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a randomized, Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab in combination with cisplatin or carboplatin + pemetrexed compared with treatment with cisplatin or carboplatin + pemetrexed in participants who are chemotherapy-naive and have Stage IV non-squamous NSCLC. Eligible participants will be randomized by a 1:1 ratio into 2 groups: Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) and Arm B (Carboplatin or Cisplatin + Pemetrexed). The study will be conducted in two phases: Induction Phase and Maintenance Phase.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Cancer-Specific Exclusions
General Medical Exclusions:
Exclusion Criteria Related to Medications and Chemotherapy:
Exclusion Criteria Related to Chemotherapy:
Primary purpose
Allocation
Interventional model
Masking
578 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal